Prostate Cancer Screening

Tim Farron Excerpts

Monday 26th October 2026 Westminster Hall

[John Lamont]

My right hon. Friend makes an important point. My ask is that the Government continue their engagement, but also keep assessing the evidence and information coming forward, so that patients are given the best possible opportunity for survival.

The uncertainty around screening matters the most for black men, as one in four will develop prostate cancer and they are around twice as likely to die from it, but rather than being offered screening, they are being invited to take part in a trial. Transform has received up to a further £18 million to directly test several relevant questions, and to ensure that if stage 1 of the project is successful, all eligible black men aged between 45 and 74 will be invited to stage 2. Researchers told me that useful stage 1 evidence should be available before the long-term trial is complete, and will be fed back to the UK NSC.

As the MP for the Scottish Borders, I want to highlight Scotland’s experience. The Scottish Prostate Cancer Initiative, supported by Sir Chris Hoy, Sir Tom Hunter, Professor Sir Chris Evans and Kenny Logan, aims to offer free PSA tests to 25,000 men aged 40 to 80 during 2026. Sir Chris described the initiative as

“a major step forward for prostate cancer testing.”

In May, 313 men were tested in Hawick and 515 men were tested in Galashiels, meaning that across two days 828 men in my constituency were tested. The initiative is not an NHS screening programme, but its community-based model may offer useful lessons about access, uptake and reaching men who might otherwise be missed. That matters, because inequalities remain stark. Analysis from the NHS, National Services Scotland and Macmillan Cancer Support found that men in the most deprived areas had a 98% higher risk of death from prostate cancer than those in the least deprived areas.

I hope the Minister can address several points. First, will she commit to independent expert scrutiny of the UK NSC modelling, and to publish the findings and the Committee’s response in full? Secondly, as stage 1 of Transform produces significant new evidence, particularly on the screening of black men, will the Government ask the UK NSC to review its recommendation? Thirdly, how will the NHS proactively identify eligible BRCA2 carriers, particularly men whose genetic risk is not already known?

Fourthly, what lessons on improving access to testing can be drawn from community-based initiatives in Scotland? Fifthly, what discussions has the Minister had with the Scottish Government and the other devolved Governments to ensure that a man’s access to screening does not depend on which side of the border he lives on? Finally, what will the Government do to make sure that the many men who fall outside the programme know they can ask their GP for a PSA test and receive clear, balanced information when they do?

[Tim Farron (Westmorland and Lonsdale) (LD)]

I had the joy of spending time with the Kendal and South Lakes prostate cancer support group just a few weeks ago. Like the hon. Gentleman and me, its members are massively in favour of increased screening and making sure there is default screening for men over 50. Does the hon. Gentleman also think the Government need to be aware that if we test more people earlier and identify cancers earlier, more people can be treated? Does he believe the Government have done enough work, both north of the border and in the UK Parliament, to ensure that we have sufficient capacity for surgery, radiotherapy and chemotherapy so that we can treat the people who are diagnosed?

[John Lamont]

That is a key point, because not everybody who is diagnosed with prostate cancer will necessarily need further treatment. Some people will not die of prostate cancer but will die with prostate cancer. The challenge for the Government is getting the balance right between when it is appropriate to test and treat and when it is not.

I am conscious that many Members want to speak, so let me conclude. Screening is not simple. Finding more cancer is not automatically the same as saving more lives, but legitimate concerns about overdiagnosis should not prevent us from asking whether advances in diagnosis have changed where the balance now lies. More than 100,000 people have asked Parliament to consider targeted screening for men at higher risk. Since they signed the petition, targeted prostate cancer screening has entered policy for the first time. That is an important first step. The question now is how and when the boundary should move as the evidence develops.

The evidence I heard when preparing for this debate points both ways. Earlier detection could save lives, but questions remain over whether modern screening can reduce past harms. The Transform trial should help to provide the answers. When it reports, the Government must be ready to act quickly; that is what the petitioners asked for and what I hope the Minister will commit to. I look forward to hearing from her and from colleagues.